SI2975025T1 - Tioacetate compounds, compositions and procedures of use - Google Patents
Tioacetate compounds, compositions and procedures of use Download PDFInfo
- Publication number
- SI2975025T1 SI2975025T1 SI201131491T SI201131491T SI2975025T1 SI 2975025 T1 SI2975025 T1 SI 2975025T1 SI 201131491 T SI201131491 T SI 201131491T SI 201131491 T SI201131491 T SI 201131491T SI 2975025 T1 SI2975025 T1 SI 2975025T1
- Authority
- SI
- Slovenia
- Prior art keywords
- alkyl
- compound
- compound according
- formula
- gout
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 title claims abstract 3
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical class CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract 4
- 229940116269 uric acid Drugs 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 201000005569 Gout Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 201000001431 Hyperuricemia Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 208000018121 Hypoxanthine-guanine phosphoribosyltransferase deficiency Diseases 0.000 claims 2
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims 2
- 102000005773 Xanthine dehydrogenase Human genes 0.000 claims 2
- 108010091383 Xanthine dehydrogenase Proteins 0.000 claims 2
- 108010093894 Xanthine oxidase Proteins 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical group C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 claims 1
- CBXQKUGCNWDBTR-UHFFFAOYSA-N 1-[3-(4-cyanophenyl)pyridin-4-yl]sulfanylcyclopropane-1-carboxylic acid Chemical compound C=1C=NC=C(C=2C=CC(=CC=2)C#N)C=1SC1(C(=O)O)CC1 CBXQKUGCNWDBTR-UHFFFAOYSA-N 0.000 claims 1
- UBVZQGOVTLIHLH-UHFFFAOYSA-N 4-[5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl]-pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 UBVZQGOVTLIHLH-UHFFFAOYSA-N 0.000 claims 1
- 206010007027 Calculus urinary Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108700017799 HPRT-Related Gout Proteins 0.000 claims 1
- 208000027408 HRPT-related hyperuricemia Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 229940122272 Oxidoreductase inhibitor Drugs 0.000 claims 1
- 208000035318 Partial hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims 1
- 229940083914 URAT1 inhibitor Drugs 0.000 claims 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229960005101 febuxostat Drugs 0.000 claims 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000002457 oxidoreductase inhibitor Substances 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229950004176 topiroxostat Drugs 0.000 claims 1
- 208000008281 urolithiasis Diseases 0.000 claims 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35549110P | 2010-06-16 | 2010-06-16 | |
| EP15166826.6A EP2975025B1 (en) | 2010-06-16 | 2011-06-15 | Thioacetate compounds, compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2975025T1 true SI2975025T1 (en) | 2018-08-31 |
Family
ID=45348850
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131491T SI2975025T1 (en) | 2010-06-16 | 2011-06-15 | Tioacetate compounds, compositions and procedures of use |
| SI201130639T SI2712861T1 (sl) | 2010-06-16 | 2011-06-15 | Spojine in sestavki tioacetata in postopki uporabe |
| SI201130149T SI2585437T1 (sl) | 2010-06-16 | 2011-06-15 | Spojine in sestavki tioacetata in postopki uporabe |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130639T SI2712861T1 (sl) | 2010-06-16 | 2011-06-15 | Spojine in sestavki tioacetata in postopki uporabe |
| SI201130149T SI2585437T1 (sl) | 2010-06-16 | 2011-06-15 | Spojine in sestavki tioacetata in postopki uporabe |
Country Status (41)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2582664A4 (en) | 2010-06-16 | 2014-07-09 | Ardea Biosciences Inc | PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| EA026101B1 (ru) * | 2011-11-03 | 2017-03-31 | Ардеа Биосайнсиз, Инк. | Применение 3,4-дизамещенного пиридинового соединения для снижения уровня мочевой кислоты в сыворотке крови |
| RU2640588C2 (ru) | 2012-11-14 | 2018-01-10 | Тейдзин Фарма Лимитед | Производное пиридина |
| CN104470898B (zh) | 2013-05-13 | 2016-04-06 | 上海恒瑞医药有限公司 | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 |
| JP6322704B2 (ja) | 2013-06-27 | 2018-05-09 | エルジー・ケム・リミテッド | Ｇｐｒ１２０アゴニストとしてのビアリール誘導体 |
| RS56837B1 (sr) * | 2014-05-13 | 2018-04-30 | Teijin Pharma Ltd | Derivat pirazina |
| CN105439946B (zh) | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
| MY189770A (en) * | 2014-12-24 | 2022-03-04 | Lg Chemical Ltd | Biaryl derivative as gpr120 agonists |
| CA2971125C (en) * | 2014-12-29 | 2024-05-21 | Nippon Chemiphar Co., Ltd. | Urat1 inhibitor |
| WO2017028762A1 (zh) * | 2015-08-14 | 2017-02-23 | 广东东阳光药业有限公司 | 一种萘环化合物的晶型 |
| CN105418495B (zh) * | 2015-11-25 | 2018-09-14 | 乳源瑶族自治县大众药品贸易有限公司 | 一种硫醚的制备方法 |
| BR112018011390B1 (pt) | 2015-12-07 | 2024-01-09 | Hinova Pharmaceuticals Inc | Compostos de quinolina, método de preparação dos mesmos, e uso dos mesmos como fármaco inibidor de transportador de urato |
| US20180360761A1 (en) * | 2015-12-08 | 2018-12-20 | Ardea Biosciences, Inc. | Pharmaceutical composition comprising a potent inhibitor of urat1 |
| WO2017114352A1 (en) | 2015-12-28 | 2017-07-06 | Chongqing Fochon Pharmaceutical Co., Ltd. | Indolizine derivatives, composition and methods of use |
| WO2017121308A1 (en) * | 2016-01-11 | 2017-07-20 | Chongqing Fochon Pharmaceutical Co., Ltd. | Fused pyridine compounds, compositions and methods of use |
| TN2018000287A1 (en) * | 2016-02-15 | 2020-01-16 | Hopitaux Paris Assist Publique | Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual |
| CN105884807A (zh) * | 2016-04-26 | 2016-08-24 | 昆药集团股份有限公司 | 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法 |
| CN106117130A (zh) * | 2016-06-28 | 2016-11-16 | 昆药集团股份有限公司 | 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物 |
| CN106083847B (zh) * | 2016-08-03 | 2018-10-30 | 山东大学 | 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用 |
| EP3538151B1 (en) | 2016-11-11 | 2024-06-26 | Whitehead Institute for Biomedical Research | Human plasma-like medium |
| CN106748987B (zh) * | 2016-11-18 | 2019-05-31 | 昆药集团股份有限公司 | 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型 |
| US20200077658A1 (en) | 2016-12-16 | 2020-03-12 | Basf Se | Pesticidal Compounds |
| CN106883169A (zh) * | 2017-04-01 | 2017-06-23 | 浙江永宁药业股份有限公司 | 一种3‑(4‑氰基‑1‑萘基)‑4‑卤代吡啶的制备方法及其应用 |
| WO2018202039A1 (zh) * | 2017-05-03 | 2018-11-08 | 成都海创药业有限公司 | 杂环化合物及其制备方法 |
| TW201922706A (zh) * | 2017-10-04 | 2019-06-16 | 日商日本煙草產業股份有限公司 | 含氮雜芳基化合物及該化合物之醫藥用途 |
| CN107955029B (zh) * | 2017-12-07 | 2020-08-11 | 成都美域高制药有限公司 | 一种雷西纳德的制备方法 |
| CN108069940B (zh) * | 2017-12-20 | 2021-04-30 | 广东赛烽医药科技有限公司 | 硫代乙酸化合物、组合物及其应用 |
| CN108084153A (zh) * | 2017-12-20 | 2018-05-29 | 广东赛烽医药科技有限公司 | 吡啶基硫代乙酸化合物、组合物及其应用 |
| CN108440397B (zh) * | 2018-03-06 | 2020-06-05 | 南方医科大学 | 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用 |
| WO2019183835A1 (en) | 2018-03-28 | 2019-10-03 | Inventisbio Shanghai Ltd. | Novel salt forms of urat-1 inhibitors |
| CN109608432B (zh) * | 2018-12-17 | 2022-10-11 | 江苏艾立康医药科技有限公司 | 作为urat1抑制剂的噻吩类衍生物 |
| CR20220069A (es) | 2019-07-16 | 2022-03-24 | Astrazeneca Ab | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad |
| CN114315705B (zh) * | 2020-09-29 | 2024-02-20 | 杭州中美华东制药有限公司 | 一类urat1抑制剂及其制备方法与用途 |
| CN114621136B (zh) * | 2020-12-09 | 2023-11-07 | 江苏正大清江制药有限公司 | 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用 |
| CA3210595A1 (en) * | 2021-03-01 | 2022-09-09 | Oskari KARJALAINEN | Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor |
| AR124985A1 (es) * | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| CN118439998A (zh) * | 2021-05-19 | 2024-08-06 | 江苏正大清江制药有限公司 | 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用 |
| CN113979931B (zh) * | 2021-10-08 | 2023-06-13 | 南方医科大学 | 一种吡啶3-胺衍生物及其制备方法和应用 |
| CN114214361A (zh) * | 2022-01-07 | 2022-03-22 | 中国农业科学院兰州兽医研究所 | 一种urat1人源化小鼠模型的构建方法及其应用 |
| WO2025060752A1 (zh) * | 2023-09-19 | 2025-03-27 | 湘北威尔曼制药股份有限公司 | 一种硫醚衍生物及其制备方法和应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE642046A (enExample) * | 1963-01-03 | |||
| ES475100A1 (es) * | 1977-11-21 | 1979-12-01 | Hoechst Ag | Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos |
| JPS6054310B2 (ja) | 1979-02-21 | 1985-11-29 | 三井東圧化学株式会社 | ピリダジン誘導体と農園芸用殺菌剤 |
| US4889868A (en) | 1984-12-20 | 1989-12-26 | Rorer Pharmaceutical Corporation | Bis-imidazolinoamino derivatives as antiallergy compounds |
| US5051442A (en) | 1990-04-25 | 1991-09-24 | Merrell Dow Pharmaceuticals Inc. | 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof |
| DE122008000051I1 (de) | 1990-11-30 | 2009-02-05 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
| US5405873A (en) * | 1992-09-10 | 1995-04-11 | Banyu Pharmaceutical Co., Ltd. | Substituted acetamide derivatives |
| JPH06234732A (ja) * | 1992-09-10 | 1994-08-23 | Banyu Pharmaceut Co Ltd | 置換アセトアミド誘導体 |
| US5344651A (en) | 1993-07-23 | 1994-09-06 | The Procter & Gamble Company | Cyproterone acetate thioacetate |
| US5580979A (en) | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5945425A (en) | 1994-04-29 | 1999-08-31 | G.D. Searle & Co. | Method of using (H+ /K+)ATPase inhibitors as antiviral agents |
| US6017925A (en) | 1997-01-17 | 2000-01-25 | Merck & Co., Inc. | Integrin antagonists |
| ATE377003T1 (de) * | 1999-01-22 | 2007-11-15 | Elan Pharm Inc | Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren |
| GB0108339D0 (en) | 2001-04-03 | 2001-05-23 | Syngenta Participations Ag | Organics compounds |
| EA014737B1 (ru) | 2004-08-25 | 2011-02-28 | Ардеа Байосайенсиз, Инк. | S-ТРИАЗОЛИЛ-α-МЕРКАПТОАЦЕТАНИЛИДЫ В КАЧЕСТВЕ ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИЧ |
| WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| US20070135437A1 (en) * | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| CA2608821A1 (en) | 2005-06-15 | 2006-12-28 | Shibo Jiang | Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
| US20070099970A1 (en) * | 2005-08-19 | 2007-05-03 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain |
| US20090131384A1 (en) | 2006-03-22 | 2009-05-21 | Syndexa Pharmaceuticals Corporation | Compounds and methods for treatment of disorders associated with er stress |
| AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| EP2402314B1 (en) * | 2007-04-11 | 2013-07-31 | Kissei Pharmaceutical Co., Ltd. | (Aza)indole derivative and use thereof for medical purposes |
| NZ585583A (en) | 2007-11-27 | 2011-09-30 | Ardea Biosciences Inc | Novel compounds and compositions and methods of use |
| EA023500B1 (ru) | 2008-09-04 | 2016-06-30 | Ардеа Биосайнсиз, Инк. | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты |
| US8173690B2 (en) * | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| WO2010048592A1 (en) | 2008-10-24 | 2010-04-29 | Ardea Biosciences, Inc. | Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof |
| US20120122780A1 (en) | 2009-05-20 | 2012-05-17 | Ardea Biosciences Inc. | Compounds, Compositions and Methods for Modulating Uric Acid Levels |
| CA2760940A1 (en) | 2009-05-20 | 2010-11-25 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
| WO2011044140A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Substituted thioacetic acid salicylate derivatives and their uses |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| EP2582664A4 (en) | 2010-06-16 | 2014-07-09 | Ardea Biosciences Inc | PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE |
| EA026101B1 (ru) * | 2011-11-03 | 2017-03-31 | Ардеа Биосайнсиз, Инк. | Применение 3,4-дизамещенного пиридинового соединения для снижения уровня мочевой кислоты в сыворотке крови |
-
2011
- 2011-06-14 AR ARP110102068A patent/AR081930A1/es active IP Right Grant
- 2011-06-15 CN CN201410141662.0A patent/CN103864677B/zh active Active
- 2011-06-15 SI SI201131491T patent/SI2975025T1/en unknown
- 2011-06-15 ME MEP-2015-173A patent/ME02302B/me unknown
- 2011-06-15 SG SG10201702527TA patent/SG10201702527TA/en unknown
- 2011-06-15 PT PT151668266T patent/PT2975025T/pt unknown
- 2011-06-15 DK DK13198843.8T patent/DK2712861T3/en active
- 2011-06-15 CN CN201180029484.7A patent/CN103068801B/zh active Active
- 2011-06-15 PT PT131988438T patent/PT2712861E/pt unknown
- 2011-06-15 EP EP19178229.1A patent/EP3611167A1/en not_active Withdrawn
- 2011-06-15 EP EP11796396.7A patent/EP2585437B1/en active Active
- 2011-06-15 PE PE2012002423A patent/PE20131047A1/es active IP Right Grant
- 2011-06-15 RS RS20140227A patent/RS53301B/sr unknown
- 2011-06-15 HU HUE13198843A patent/HUE025962T2/en unknown
- 2011-06-15 HR HRP20140391AT patent/HRP20140391T1/hr unknown
- 2011-06-15 ME MEP-2014-42A patent/ME01830B/me unknown
- 2011-06-15 LT LTEP15166826.6T patent/LT2975025T/lt unknown
- 2011-06-15 PT PT117963967T patent/PT2585437E/pt unknown
- 2011-06-15 BR BR112012032028-9A patent/BR112012032028B1/pt active IP Right Grant
- 2011-06-15 MY MYPI2012005401 patent/MY153039A/en unknown
- 2011-06-15 TW TW100120935A patent/TWI460173B/zh active
- 2011-06-15 SG SG2012091195A patent/SG186298A1/en unknown
- 2011-06-15 PL PL11796396T patent/PL2585437T3/pl unknown
- 2011-06-15 MX MX2012014863A patent/MX2012014863A/es active IP Right Grant
- 2011-06-15 JP JP2013515492A patent/JP5551310B2/ja active Active
- 2011-06-15 HU HUE15166826A patent/HUE040209T2/hu unknown
- 2011-06-15 SI SI201130639T patent/SI2712861T1/sl unknown
- 2011-06-15 EA EA201270803A patent/EA022933B1/ru unknown
- 2011-06-15 EP EP13198843.8A patent/EP2712861B1/en active Active
- 2011-06-15 DK DK11796396.7T patent/DK2585437T3/da active
- 2011-06-15 UA UAA201300527A patent/UA107115C2/ru unknown
- 2011-06-15 SI SI201130149T patent/SI2585437T1/sl unknown
- 2011-06-15 SM SM20180304T patent/SMT201800304T1/it unknown
- 2011-06-15 RS RS20180652A patent/RS57363B1/sr unknown
- 2011-06-15 ES ES13198843.8T patent/ES2551114T3/es active Active
- 2011-06-15 AU AU2011268360A patent/AU2011268360B2/en active Active
- 2011-06-15 MX MX2014004120A patent/MX343583B/es unknown
- 2011-06-15 DK DK15166826.6T patent/DK2975025T3/en active
- 2011-06-15 US US13/703,890 patent/US10266493B2/en active Active
- 2011-06-15 CA CA2802535A patent/CA2802535C/en active Active
- 2011-06-15 ES ES15166826.6T patent/ES2673426T3/es active Active
- 2011-06-15 RS RS20150668A patent/RS54375B1/sr unknown
- 2011-06-15 PL PL15166826T patent/PL2975025T3/pl unknown
- 2011-06-15 EP EP15166826.6A patent/EP2975025B1/en active Active
- 2011-06-15 CU CU20120170A patent/CU24126B1/es active IP Right Grant
- 2011-06-15 TW TW103135886A patent/TWI501949B/zh active
- 2011-06-15 PL PL13198843T patent/PL2712861T3/pl unknown
- 2011-06-15 KR KR1020137000923A patent/KR101432950B1/ko active Active
- 2011-06-15 PH PH1/2012/502460A patent/PH12012502460A1/en unknown
- 2011-06-15 ES ES11796396.7T patent/ES2459146T3/es active Active
- 2011-06-15 WO PCT/US2011/040585 patent/WO2011159839A2/en not_active Ceased
- 2011-06-15 TR TR2018/08344T patent/TR201808344T4/tr unknown
- 2011-06-15 KR KR1020147006531A patent/KR101608604B1/ko active Active
- 2011-06-15 EP EP18159710.5A patent/EP3409661A1/en not_active Withdrawn
-
2012
- 2012-12-04 IL IL223435A patent/IL223435A/en active IP Right Grant
- 2012-12-13 GT GT201200339A patent/GT201200339A/es unknown
- 2012-12-13 HN HN2012002664A patent/HN2012002664A/es unknown
- 2012-12-14 CL CL2012003546A patent/CL2012003546A1/es unknown
- 2012-12-14 DO DO2012000314A patent/DOP2012000314A/es unknown
- 2012-12-17 CO CO12228040A patent/CO6640311A2/es active IP Right Grant
- 2012-12-18 ZA ZA2012/09574A patent/ZA201209574B/en unknown
- 2012-12-18 CR CR20120649A patent/CR20120649A/es unknown
- 2012-12-20 EC ECSP12012353 patent/ECSP12012353A/es unknown
-
2013
- 2013-04-04 US US13/857,108 patent/US8541589B2/en active Active
- 2013-06-07 US US13/913,272 patent/US8629278B2/en active Active
-
2014
- 2014-04-24 SM SM201400055T patent/SMT201400055B/xx unknown
- 2014-05-21 JP JP2014105611A patent/JP5768166B2/ja active Active
- 2014-12-03 IL IL236039A patent/IL236039A0/en active IP Right Grant
-
2015
- 2015-06-15 JP JP2015120633A patent/JP6112318B2/ja active Active
- 2015-10-19 HR HRP20151105TT patent/HRP20151105T1/hr unknown
- 2015-10-22 SM SM201500260T patent/SMT201500260B/it unknown
-
2017
- 2017-02-27 JP JP2017035549A patent/JP6364515B2/ja active Active
-
2018
- 2018-05-25 HR HRP20180829TT patent/HRP20180829T1/hr unknown
- 2018-06-27 CY CY20181100629T patent/CY1120337T1/el unknown
- 2018-06-28 JP JP2018123691A patent/JP2018168174A/ja active Pending
- 2018-11-14 US US16/190,925 patent/US10919858B2/en active Active
-
2020
- 2020-12-16 US US17/123,380 patent/US20210171466A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2975025T1 (en) | Tioacetate compounds, compositions and procedures of use | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| RU2486181C2 (ru) | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ | |
| IL287030A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy | |
| JP2017524704A5 (enExample) | ||
| EA200701416A1 (ru) | Производные фениламида 4-(бензил)пиперазин-1-карбоновой кислоты и родственные соединения в качестве модуляторов амида жирной кислоты гидролазы для лечения страхов, боли и других состояний | |
| JP2016536363A5 (enExample) | ||
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| NO20071042L (no) | 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer | |
| RU2012131341A (ru) | Индол-пиперидинилбензиламины как ингибиторы бета-триптазы | |
| RU2019121871A (ru) | Новые производные фенилпропионовой кислоты и их применение | |
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| NZ593413A (en) | Combinations comprising methotrexate and dhodh inhibitors | |
| JP2007525516A5 (enExample) | ||
| EA201000268A1 (ru) | Производные n-(ариламино)сульфонамидов, включая полиморфы, в качестве ингибиторов mek, а также композиции, способы применения и способы их приготовления | |
| WO2006127503A3 (en) | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | |
| RU2011143741A (ru) | Производное индолизина и его применение в медицинских целях | |
| CL2008002142A1 (es) | Compuestos derivados de 2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}tio)-4-[4-(2-hidroxietoxi) fenil] piridin-3,5-dicarbonitrilo; procedimiento de preparacion; composicion farmaceutica y uso en enfermedades cardiovasculares. | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| CA2680617A1 (en) | Use of n2-phenylamidines as herbicides | |
| NZ605690A (en) | Oxadiazole inhibitors of leukotriene production | |
| RU2013127155A (ru) | Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы | |
| RU2015107550A (ru) | Новые фенилпиридин/пиразинамиды для лечения рака | |
| PE20091213A1 (es) | Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico | |
| EA201101298A1 (ru) | Аддитивные соли трометамина с производными азабифениламинобензойной кислоты в качестве ингибиторов dhodh |